{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,14]],"date-time":"2025-02-14T05:25:44Z","timestamp":1739510744690,"version":"3.37.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T00:00:00Z","timestamp":1739232000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diagn Pathol"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Objective<\/jats:title>\n            <jats:p>The C216T mutation in the TERT promoter (TERTp) is a rarely reported genetic alteration in papillary thyroid carcinoma (PTC). Its clinical significance remains unclear. This study aimed to compare the impact of the C216T and hot spot mutations (C228T and C250T) of TERTp on the clinicopathologic characteristics and the expression of S100A10, a member of the S100 protein family, in PTC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>In this retrospective study, a cohort comprising 8 PTC cases with the C216T mutation, 12 cases with the hot spot mutations, and 120 cases with the wildtype genotype was established. The influence of TERTp mutations on the clinicopathologic profiles of PTC was assessed.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>The C216T mutation was mutually exclusive with the hot spot mutations and its frequency (0.19%) fell between that of C228T (0.68%) and C250T (0.06%). Compared to PTC cases with the wildtype genotype, cases with C216T mutations did not exhibit significant differences in clinicopathologic characteristics and S100A10 expression levels. In contrast, the hot spot mutations were positively associated with extrathyroidal extension (<jats:italic>p<\/jats:italic>\u2009=\u20090.001), ATA recurrence risk (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), AJCC staging (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001), and increased expression of S100A10 (<jats:italic>p<\/jats:italic>\u2009=\u20090.005). Furthermore, a significant correlation was found between S100A10 expression and extrathyroidal extension (<jats:italic>p<\/jats:italic>\u2009=\u20090.005), lymph node metastasis (<jats:italic>p<\/jats:italic>\u2009=\u20090.013), and ATA recurrence risk (<jats:italic>p<\/jats:italic>\u2009=\u20090.023).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>The C216T mutation did not induce the aggressiveness of PTC as the hot spot mutations did. Furthermore, the hot spot mutations were closely associated with the increased expression of S100A10. The latter may contribute to the pro-invasive effect of the hot spot mutations on PTC.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s13000-025-01613-6","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T15:00:40Z","timestamp":1739286040000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The impact of C216T and hot spot mutations of the TERT promoter on the clinicopathologic characteristics and S100A10 expression in papillary thyroid carcinoma: a comparative study"],"prefix":"10.1186","volume":"20","author":[{"given":"Ping","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huihui","family":"Gui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,2,11]]},"reference":[{"issue":"4","key":"1613_CR1","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1089\/thy.2021.0557","volume":"32","author":"E Pasqual","year":"2018","unstructured":"Pasqual E, Sosa JA, Chen Y, et al. Trends in the management of localized papillary thyroid carcinoma in the United States (2000\u20132018). Thyroid. 2018;32(4):397\u2013410.","journal-title":"Thyroid"},{"issue":"13","key":"1613_CR2","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1001\/jama.2017.2719","volume":"317","author":"H Lim","year":"2017","unstructured":"Lim H, Devesa SS, Sosa JA, et al. Trends in thyroid cancer incidence and mortality in the United States, 1974\u20132013. JAMA. 2017;317(13):1338\u201348.","journal-title":"JAMA"},{"issue":"12","key":"1613_CR3","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1093\/annonc\/mdz400","volume":"30","author":"S Filetti","year":"2019","unstructured":"Filetti S, Durante C, Hartl D, Leboulleux S, et al. Thyroid cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2019;30(12):1856\u201383.","journal-title":"Ann Oncol"},{"issue":"7","key":"1613_CR4","doi-asserted-by":"publisher","first-page":"3112","DOI":"10.1007\/s12325-020-01391-1","volume":"37","author":"A Coca-Pelaz","year":"2020","unstructured":"Coca-Pelaz A, Shah JP, Hernandez-Prera JC, et al. Papillary thyroid cancer-aggressive variants and impact on management: a narrative review. Adv Ther. 2020;37(7):3112\u201328.","journal-title":"Adv Ther"},{"issue":"3","key":"1613_CR5","doi-asserted-by":"publisher","first-page":"220","DOI":"10.4158\/EP-2018-0436","volume":"25","author":"T Tian","year":"2019","unstructured":"Tian T, Kou Y, Huang R, et al. Prognosis of high-risk papillary thyroid cancer patients with pre-ablation stimulated tg\u2009<\u20091 ng\/ml. Endocr Pract. 2019;25(3):220\u201325.","journal-title":"Endocr Pract"},{"issue":"9871","key":"1613_CR6","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","volume":"381","author":"M Xing","year":"2013","unstructured":"Xing M, Haugen BR, Schlumberger M. Progress in molecular-based management of differentiated thyroid cancer. Lancet. 2013;381(9871):1058\u201369.","journal-title":"Lancet"},{"issue":"3","key":"1613_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.7150\/ijms.29935","volume":"16","author":"MI Abdullah","year":"2019","unstructured":"Abdullah MI, Junit SM, Ng KL, et al. Papillary thyroid cancer: genetic alterations and molecular biomarker investigations. Int J Med Sci. 2019;16(3):450\u201360.","journal-title":"Int J Med Sci"},{"key":"1613_CR8","doi-asserted-by":"publisher","first-page":"589929","DOI":"10.3389\/fimmu.2020.589929","volume":"11","author":"M Dratwa","year":"2020","unstructured":"Dratwa M, Wysocza\u0144ska B, \u0141acina P, et al. TERT-regulation and roles in cancer formation. Front Immunol. 2020;11:589929.","journal-title":"Front Immunol"},{"issue":"13","key":"1613_CR9","doi-asserted-by":"publisher","first-page":"5831","DOI":"10.1002\/cam4.2467","volume":"8","author":"F Panebianco","year":"2019","unstructured":"Panebianco F, Nikitski AV, Nikiforova MN, et al. Spectrum of TERT promoter mutations and mechanisms of activation in thyroid cancer. Cancer Med. 2019;8(13):5831\u201339.","journal-title":"Cancer Med"},{"issue":"3","key":"1613_CR10","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1530\/ERC-15-0533","volume":"23","author":"R Liu","year":"2016","unstructured":"Liu R, Xing M. TERT promoter mutations in thyroid cancer. Endocr Relat Cancer. 2016;23(3):143\u201355.","journal-title":"Endocr Relat Cancer"},{"key":"1613_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ejca.2018.12.003","volume":"108","author":"C Bournaud","year":"2019","unstructured":"Bournaud C, Descotes F, Decaussin-Petrucci M, et al. TERT promoter mutations identify a high-risk group in metastasis-free advanced thyroid carcinoma. Eur J Cancer. 2019;108:41\u20139.","journal-title":"Eur J Cancer"},{"issue":"4","key":"1613_CR12","doi-asserted-by":"publisher","first-page":"648","DOI":"10.3390\/cancers13040648","volume":"13","author":"J Park","year":"2021","unstructured":"Park J, Lee S, Kim K, et al. TERT promoter mutations and the 8th Edition TNM classification in predicting the survival of thyroid cancer patients. Cancers (Basel). 2021;13(4):648.","journal-title":"Cancers (Basel)"},{"issue":"5","key":"1613_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/cen.14316","volume":"94","author":"B Chen","year":"2021","unstructured":"Chen B, Shi Y, Xu Y, et al. The predictive value of coexisting BRAFV600E and TERT promoter mutations on poor outcomes and high tumour aggressiveness in papillary thyroid carcinoma: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2021;94(5):731\u201342.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"2","key":"1613_CR14","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1111\/cen.13017","volume":"85","author":"DT Yin","year":"2016","unstructured":"Yin DT, Yu K, Lu RQ, et al. Clinicopathological significance of TERT promoter mutation in papillary thyroid carcinomas: a systematic review and meta-analysis. Clin Endocrinol (Oxf). 2016;85(2):299\u2013305.","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"10","key":"1613_CR15","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.3390\/jcm10102179","volume":"10","author":"YS Choi","year":"2021","unstructured":"Choi YS, Choi SW, Yi JW. Prospective analysis of TERT promoter mutations in papillary thyroid carcinoma at a single institution. J Clin Med. 2021;10(10):2179.","journal-title":"J Clin Med"},{"issue":"4","key":"1613_CR16","doi-asserted-by":"publisher","first-page":"310","DOI":"10.4132\/jptm.2020.05.12","volume":"54","author":"SY Kim","year":"2020","unstructured":"Kim SY, Kim T, Kim K, et al. Highly prevalent BRAF V600E and low-frequency TERT promoter mutations underlie papillary thyroid carcinoma in Koreans. J Pathol Transl Med. 2020;54(4):310\u201317.","journal-title":"J Pathol Transl Med"},{"issue":"3","key":"1613_CR17","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1016\/j.lungcan.2014.10.009","volume":"86","author":"X Ma","year":"2014","unstructured":"Ma X, Gong R, Wang R, et al. Recurrent TERT promoter mutations in non-small cell lung cancers. Lung Cancer. 2014;86(3):369\u201373.","journal-title":"Lung Cancer"},{"issue":"2","key":"1613_CR18","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1002\/ijc.28360","volume":"134","author":"Y Zhao","year":"2014","unstructured":"Zhao Y, Gao Y, Chen Z, et al. Low frequency of TERT promoter somatic mutation in 313 sporadic esophageal squamous cell carcinomas. Int J Cancer. 2014;134(2):493\u201394.","journal-title":"Int J Cancer"},{"issue":"11","key":"1613_CR19","doi-asserted-by":"publisher","first-page":"2528","DOI":"10.1002\/hed.25385","volume":"40","author":"MN Chien","year":"2018","unstructured":"Chien MN, Yang PS, Hsu YC, et al. Transcriptome analysis of papillary thyroid cancer harboring telomerase reverse transcriptase promoter mutation. Head Neck. 2018;40(11):2528\u201337.","journal-title":"Head Neck"},{"issue":"6","key":"1613_CR20","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.3390\/cancers12061597","volume":"12","author":"D Rusinek","year":"2020","unstructured":"Rusinek D, Pfeifer A, Cieslicka M, et al. TERT promoter mutations and their impact on gene expression profile in papillary thyroid carcinoma. Cancers (Basel). 2020;12(6):1597.","journal-title":"Cancers (Basel)"},{"issue":"12","key":"1613_CR21","doi-asserted-by":"publisher","first-page":"4122","DOI":"10.3390\/ijms19124122","volume":"9","author":"TM Noye","year":"2018","unstructured":"Noye TM, Lokman NA, Oehler MK, et al. S100A10 and cancer hallmarks: structure, functions, and its emerging role in ovarian cancer. Int J Mol Sci. 2018;9(12):4122.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"1613_CR22","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1111\/pin.12861","volume":"69","author":"Y Saiki","year":"2019","unstructured":"Saiki Y, Horii A. Multiple functions of S100A10, an important cancer promoter. Pathol Int. 2019;69(11):629\u201336.","journal-title":"Pathol Int"},{"issue":"2","key":"1613_CR23","first-page":"1417","volume":"17","author":"NA Tantyo","year":"2019","unstructured":"Tantyo NA, Karyadi AS, Rasman SZ, et al. The prognostic value of S100A10 expression in cancer. Oncol Lett. 2019;17(2):1417\u201324.","journal-title":"Oncol Lett"},{"key":"1613_CR24","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.trsl.2016.02.002","volume":"171","author":"NA Lokman","year":"2016","unstructured":"Lokman NA, Pyragius CE, Ruszkiewicz A, et al. Annexin A2 and S100A10 are independent predictors of serous ovarian cancer outcome. Transl Res. 2016;171:83\u201395.","journal-title":"Transl Res"},{"issue":"1","key":"1613_CR25","doi-asserted-by":"publisher","first-page":"202","DOI":"10.3390\/cancers15010202","volume":"15","author":"H Lin","year":"2022","unstructured":"Lin H, Yang P, Li B, et al. S100A10 promotes pancreatic ductal adenocarcinoma cells proliferation, migration and adhesion through JNK\/LAMB3-LAMC2 axis. Cancers (Basel). 2022;15(1):202.","journal-title":"Cancers (Basel)"},{"issue":"7","key":"1613_CR26","doi-asserted-by":"publisher","first-page":"1370","DOI":"10.1136\/gutjnl-2022-327998","volume":"72","author":"X Wang","year":"2023","unstructured":"Wang X, Huang H, Sze KM, et al. S100A10 promotes HCC development and progression via transfer in extracellular vesicles and regulating their protein cargos. Gut. 2023;72(7):1370\u201384.","journal-title":"Gut"},{"issue":"1","key":"1613_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26(1):1\u2013133.","journal-title":"Thyroid"},{"key":"1613_CR28","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1210\/jc.2018-00081","volume":"103","author":"T Diker-Cohen","year":"2018","unstructured":"Diker-Cohen T, Hirsch D, Shimon I, et al. Impact of minimal extra-thyroid extension in differentiated thyroid cancer: systematic review and meta-analysis. J Clin Endocrinol Metab. 2018;103:2100\u201306.","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"1613_CR29","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1507\/endocrj.EJ19-0523","volume":"67","author":"S Moritani","year":"2020","unstructured":"Moritani S. Impact of gross extrathyroidal extension into major neck structures on the prognosis of papillary thyroid carcinoma according to the American Joint Committee on Cancer eighth edition. Endocr J. 2020;67(9):941\u201348.","journal-title":"Endocr J"},{"issue":"10","key":"1613_CR30","doi-asserted-by":"publisher","first-page":"2370","DOI":"10.3390\/cancers14102370","volume":"14","author":"Y Kim","year":"2022","unstructured":"Kim Y, Kim YS, Bae JS, et al. Is gross extrathyroidal extension to strap muscles (T3b) only a risk factor for recurrence in papillary thyroid carcinoma? A propensity score matching study. Cancers (Basel). 2022;14(10):2370.","journal-title":"Cancers (Basel)"},{"issue":"10","key":"1613_CR31","doi-asserted-by":"publisher","first-page":"102649","DOI":"10.1016\/j.autrev.2020.102649","volume":"19","author":"M Ralli","year":"2020","unstructured":"Ralli M, Angeletti D, Fiore M, et al. Hashimoto\u2019s thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation. Autoimmun Rev. 2020;19(10):102649.","journal-title":"Autoimmun Rev"},{"issue":"1","key":"1613_CR32","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1097\/BOR.0b013e328341378c","volume":"23","author":"Y Li","year":"2011","unstructured":"Li Y, Nishihara E, Kakudo K. Hashimoto\u2019s thyroiditis: old concepts and new insights. Curr Opin Rheumatol. 2011;23(1):102\u201307.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"1613_CR33","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1097\/PAP.0000000000000184","volume":"25","author":"MC Nath","year":"2018","unstructured":"Nath MC, Erickson LA. Aggressive variants of papillary thyroid carcinoma: hobnail, tall cell, columnar, and solid. Adv Anat Pathol. 2018;25(3):172\u201379.","journal-title":"Adv Anat Pathol"},{"issue":"3","key":"1613_CR34","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","unstructured":"Cancer Genome Atlas Research Network. Integrated genomic characterization of papillary thyroid carcinoma. Cell. 2014;159(3):676\u201390.","journal-title":"Cell"},{"issue":"4","key":"1613_CR35","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1530\/ERC-13-0210","volume":"20","author":"X Liu","year":"2013","unstructured":"Liu X, Bishop J, Shan Y, et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer. 2013;20(4):603\u201310.","journal-title":"Endocr Relat Cancer"},{"issue":"6","key":"1613_CR36","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1530\/ERC-15-0396","volume":"22","author":"E Qasem","year":"2015","unstructured":"Qasem E, Murugan AK, Al-Hindi H, et al. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population. Endocr Relat Cancer. 2015;22(6):901\u201308.","journal-title":"Endocr Relat Cancer"},{"key":"1613_CR37","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.gde.2020.02.001","volume":"60","author":"FK Lorbeer","year":"2020","unstructured":"Lorbeer FK, Hockemeyer D. TERT promoter mutations and telomeres during tumorigenesis. Curr Opin Genet Dev. 2020;60:56\u201362.","journal-title":"Curr Opin Genet Dev"},{"key":"1613_CR38","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.mrrev.2016.11.002","volume":"771","author":"B Heidenreich","year":"2017","unstructured":"Heidenreich B, Kumar R. TERT promoter mutations in telomere biology. Mutat Res Rev Mutat Res. 2017;771:15\u201331.","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"2","key":"1613_CR39","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s00109-011-0815-6","volume":"90","author":"M Nipp","year":"2012","unstructured":"Nipp M, Elsner M, Balluff B, et al. S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. J Mol Med (Berl). 2012;90(2):163\u201374.","journal-title":"J Mol Med (Berl)"},{"issue":"9","key":"1613_CR40","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1016\/j.tibs.2013.07.001","volume":"38","author":"KC Low","year":"2013","unstructured":"Low KC, Tergaonkar V. Telomerase: central regulator of all of the hallmarks of cancer. Trends Biochem Sci. 2013;38(9):426\u201334.","journal-title":"Trends Biochem Sci"},{"issue":"7","key":"1613_CR41","doi-asserted-by":"publisher","first-page":"974","DOI":"10.3390\/biom11070974","volume":"11","author":"A G\u0142owacka","year":"2021","unstructured":"G\u0142owacka A, Bieganowski P, Jurewicz E, et al. Regulation of S100A10 gene expression. Biomolecules. 2021;11(7):974.","journal-title":"Biomolecules"}],"container-title":["Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13000-025-01613-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13000-025-01613-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T15:41:38Z","timestamp":1739461298000},"score":1,"resource":{"primary":{"URL":"https:\/\/diagnosticpathology.biomedcentral.com\/articles\/10.1186\/s13000-025-01613-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,11]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1613"],"URL":"https:\/\/doi.org\/10.1186\/s13000-025-01613-6","relation":{},"ISSN":["1746-1596"],"issn-type":[{"type":"electronic","value":"1746-1596"}],"subject":[],"published":{"date-parts":[[2025,2,11]]},"assertion":[{"value":"15 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethical Committee of Peking University Shenzhen Hospital (number: [2023] No. 163). The Peking University Shenzhen Hospital Ethical Committee exempted the informed consent from the participates based on the retrospective nature of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}